The next phase of the weight-loss drug boom is taking shape — and it’s no longer just about who has the most effective injectable.
San Francisco-based biotech Structure Therapeutics (NASDAQ:GPCR) has reported Phase 2 topline results for its oral GLP-1 candidate aleniglipron, posting weight-loss outcomes the company says stack up favourably against leading next-generation drugs — including Eli Lilly and Co (NYSE:LLY)’s oral candidate orforglipron, which is widely expected to reach the market in the near term.
It’s an early-stage result, and investors have seen promising obesity drugs stumble before. But the data lands at a critical moment for a market already defined by fierce competition, supply constraints and growing pressure to move beyond injections.
Structure steps into the spotlight
Structure’s aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist, produced placebo-adjusted weight loss of around 15–16% at higher doses over 36 weeks in its mid-stage study.
That puts it broadly in line with the upper range seen in late-stage trials of Eli Lilly’s oral GLP-1 candidate orforglipron, and approaching the efficacy range of established injectable therapies.
With orforglipron approaching a potential approval window, the results sharpen the competitive backdrop for what had been expected to be one of the first widely available oral GLP-1 options — suggesting it may enter a more contested field than previously anticipated.
While cross-trial comparisons should be treated with caution, the result is enough to position Structure as a credible contender in a field that, until recently, has been dominated by Eli Lilly and Novo Nordisk (NYSE:NVO).
The company itself is a relatively new name in the obesity space. Originally focused on GPCR-targeted drug discovery, Structure pivoted towards metabolic disease as the commercial potential of GLP-1 therapies became clear, building a pipeline centred on oral, non-peptide approaches.
A more crowded oral battleground
The broader market context has shifted quickly.
Novo Nordisk has already launched an oral GLP-1 for weight management in the US, marking a step towards more accessible treatment options. Eli Lilly, meanwhile, continues to lead commercially with its injectable portfolio and is advancing orforglipron through late-stage development ahead of an expected regulatory decision.
That leaves the sector in a more competitive position than it was even a year ago. Rather than a first-mover race, the focus has turned to differentiation — with multiple companies now targeting similar levels of weight loss.
Structure’s data suggests smaller biotech players are capable of competing on efficacy, at least in early- to mid-stage studies.
Beyond efficacy: Tolerability and scale
As the field matures, efficacy alone is no longer enough to define a winner.
Tolerability remains a central issue across GLP-1 therapies, with gastrointestinal side effects common across the class. Structure has reported a safety profile broadly consistent with expectations so far, but longer-term data will be needed to assess how its drug performs at scale.
Equally important is manufacturing and distribution. Injectable GLP-1 drugs have been constrained by supply bottlenecks and complex production processes. Oral small-molecule drugs, if proven effective and safe, could offer a more scalable alternative — potentially expanding access and easing pressure on supply chains.
Implications for the market leaders
For Eli Lilly and Novo Nordisk, Structure’s results do not immediately threaten their market position.
Both companies remain far ahead in terms of approved products, commercial infrastructure and late-stage pipelines. Lilly’s oral candidate, in particular, is further advanced and still well placed to capture early share of the emerging pill-based segment if approved as expected.
But the latest data show that what was once a relatively concentrated market is becoming more competitive, with a growing number of companies demonstrating results within a similar efficacy range.
Early — but increasingly competitive
Structure Therapeutics still faces a long development pathway, with larger Phase 3 trials and regulatory hurdles ahead.
But its latest readout highlights how quickly the competitive landscape is evolving.
The oral GLP-1 market is no longer defined by a handful of frontrunners. Instead, it is shaping into a deeper, more contested field — where smaller biotech players are beginning to show they can keep pace with the industry’s biggest names.
Structure Therapeutics’ New York-listed shares rose about 5% on Monday, while Eli Lilly gained about 0.4%.